Lin, Chia-Hao
Wu, Cheng-Jang http://orcid.org/0000-0002-7640-5915
Cho, Sunglim
Patkar, Rasika http://orcid.org/0000-0002-6664-5659
Huth, William J.
Lin, Ling-Li
Chen, Mei-Chi
Israelsson, Elisabeth
Betts, Joanne
Niedzielska, Magdalena
Patel, Shefali A.
Duong, Han G.
Gerner, Romana R.
Hsu, Chia-Yun http://orcid.org/0000-0002-5283-1020
Catley, Matthew
Maciewicz, Rose A.
Chu, Hiutung http://orcid.org/0000-0001-7489-0446
Raffatellu, Manuela http://orcid.org/0000-0001-6487-4215
Chang, John T.
Lu, Li-Fan http://orcid.org/0000-0002-9727-0036
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI108651, AI127751, AI163813, AI126277, AI145325, AI154644, AI132122)
R.P. is a BioLegend fellow.
R.R.G. is partly supported by a fellowship from the Crohn’s and Colitis Foundation.
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK120515)
M.R. holds an Investigator in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund.
Department of Veterans Affairs | Veterans Affairs San Diego Healthcare System (BX005106)
Article History
Received: 24 February 2023
Accepted: 2 October 2023
First Online: 6 November 2023
Competing interests
: L.-F.L. is a scientific advisor for Elixiron Immunotherapeutics and receives research grants from AstraZeneca, Avidity Biosciences and Molecular Axiom. E.I., J.B., M.N., M.C. and R.A.M are or were employees of AstraZeneca and may own stock or stock options. As such, they declare that they are bound by confidentiality agreements that prevent them from disclosing their competing interests in this work. The remaining authors declare no competing interests.